Unique ID issued by UMIN | UMIN000035533 |
---|---|
Receipt number | R000040483 |
Scientific Title | Fulvestrant and CDK4/6 inhibitor as first line hormonal therapy for locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer -observational study |
Date of disclosure of the study information | 2019/01/13 |
Last modified on | 2023/01/29 12:50:37 |
Fulvestrant and CDK4/6 inhibitor as first line hormonal therapy for locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer -observational study
SBP-11
Fulvestrant and CDK4/6 inhibitor as first line hormonal therapy for locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer -observational study
SBP-11
Japan |
breast cancer
Breast surgery |
Malignancy
NO
To evaluate the efficacy and the safety of fulvestrant and CDK4/6 inhibitor as first line hormonal therapy for locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer.
Safety,Efficacy
PFS
CBR, OS, ORR, TTF, Safety, compliance
Observational
20 | years-old | <= |
Not applicable |
Female
Locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer pretreated with no hormonal therapy for MBC.
1 Adaptation for Fulvestrant and CDK4/6 inhibitor and the informed consent is obtained.
2 age >=20,female, regardless of menstrual status.
3 locally advanced/ metastatic breast cancer histologically confirmed
4 Hormone receptor positive breast cance confirmed by Immunohistochemically.
5 HER2 negative breast cance confirmed by Immunohistochemically or ISH.
6 ECOG PS: 0-2
7 non-hematological AE( CTCAE v4.0-JCOG) <= grade 2
7 no major organ dysfunction nor bone marrow dysfunction.
8 with or without evaluable lesions (with evaluable lesions preferred)
9 1st line hormonal therapy for MBC ( 1regimen fo chemotherapy is allowed)
10 with documented informed consent.
1 with life-threatenings
2 symptomatic brain metastasis
3 eligible for inclusion criteria of PALOMA-3
4 pretreated with hormonal therapy for MBC
5 pregnancy or breast feeding or unwilling to contraception
6 long QT syndrome or similar diseases
7 Electrolyte abnormality causing long QT syndrome
8 uncontrolled hypertension, symptomatic heart failure, unstable angina, severe arrhythmia or acute myocardial infarction within 12 months
9 obvious pulmonary fibrosis or interstitial pneumonia
10 active infection
11 other severe comorbidity
12 another active cancer
13 allergic for fulvestrant or CDK4/6 inhibitor
14 other inappropriate patients
75
1st name | Shinichiro |
Middle name | |
Last name | Kubo |
Fukuyama City Hospital
Department of Breast and thyroid surgery
721-08511
5-23-1 Zao-cho, Fukuyama city , Hiroshisma
084-941-5151
kubokubobo@yahoo.co.jp
1st name | Naruto |
Middle name | |
Last name | Taira |
Setouchi Breast Project Comprehensive Support Organization
Clinical trial committee
700-8558
2-5-1, Shikata, Kita-ku, Okayama,Japan
086-235-7265
info@setouchi-bp.com
Setouchi Breast Project Comprehensive Support Organization
Setouchi Breast Project Comprehensive Support Organization
Non profit foundation
Ethics Committee, Fukuyama City Hospital
5-23-1 Zao-cho, Fukuyama city , Hiroshisma,Japan
084-941-5151
shimin-byouin@city.fukuyama.hiroshima.jp
NO
2019 | Year | 01 | Month | 13 | Day |
Unpublished
Enrolling by invitation
2018 | Year | 11 | Month | 14 | Day |
2018 | Year | 11 | Month | 29 | Day |
2018 | Year | 12 | Month | 01 | Day |
2025 | Year | 06 | Month | 01 | Day |
clinical data
2019 | Year | 01 | Month | 13 | Day |
2023 | Year | 01 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000040483
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |